Bicara Therapeutics Earnings
NASDAQ: BCAXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
17.50+0.24 (+1.39%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Bicara Therapeutics earnings summary
In its most recent report on Aug 11, 2026 (Q2 2026), BCAX posted EPS of $-0.82. Across the last 8 reports, BCAX shares moved an average of 13.7% (in either direction) in the first trading session after results, rising 4 times and falling 4 times.
Summary generated from market data by MetaCap's automated system. Methodology
BCAX earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Aug 11, 2026 | — | $-0.82 | — | -1.6% |
| May 11, 2026 | — | $-0.93 | — | +7.2% |
| Feb 26, 2026 | — | $-0.67 | — | +10.1% |
| Nov 10, 2025 | — | $-0.67 | — | +22.1% |
| Aug 12, 2025 | — | $-0.50 | — | +1.7% |
| May 13, 2025 | — | $-0.68 | — | -35.9% |
| Mar 27, 2025 | — | $35.50 | — | -21.1% |
| Nov 12, 2024 | — | $-1.60 | — | -10.3% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.